USA Archives

Ilya Pharma enrols first patient in diabetic foot ulcer study

More News! 15 Nov 2022

Destiny Pharma’s XF-73 dermal infection project advances to safety study

The second of two planned preclinical safety studies has started for Destiny Pharma’s XF-73 dermal formulation. The company announced the start of an investigational new drug (IND) today (November 15) and is developing the formulation for the prevention of infections associated with open wounds and broken skin including diabetic foot ulcers (DFUs). This second study […]

November 15, 2022 - 2 minutesmins - By Liza Laws

News and Trends 14 Nov 2022

Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy

Nutcracker Therapeutics, Inc. has presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting. The company said the data demonstrate that NTX-250 has the ability to elicit strong anti-tumor responses in C3.43 murine tumor models and induce an immune response in […]

November 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

New therapy transitions toxic immune cells from harmful to healing to fight effects of hyperinflammation in children

When we think about acute kidney injury (AKI) and multi-organ failure, we don’t often think about children. But approximately 4,000 pediatric patients in the U.S. each year have AKI requiring continual kidney replacement therapy (CKRT). These patient profiles are associated with long hospital stays, high morbidity and mortality (50%), and children who survive an AKI […]

November 14, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

A biotech boom manifesting real results in rare pediatric diseases

By Bob Coughlin, managing director, life sciences, JLL For the last two years, the pandemic has resulted in the explosive growth in life sciences. The world watched in awe and anticipation as biotech successfully raced to develop vaccines, therapeutics and diagnostics for Covid-19. It has been a good moment for an industry that deserves such […]

November 14, 2022 - 5 minutesmins - By External Contributor

News and Trends 11 Nov 2022

Beyond Biotech podcast 22: PacBio, Sierra Space

This week, we have two longer interviews. We have conversations with Neil Ward, VP of PacBio EMEA, and Marc Giulianotti, senior manager in space biomanufacturing at Sierra Space. We also have our weekly contribution from global commercial real estate services company JLL, with Travis McCready. Sierra Space and UC San Diego to develop first stem […]

November 11, 2022

News and Trends 10 Nov 2022

SOTIO reveal potential treatment for adults with solid tumors at SITC meeting

SOTIO Biotech has presented preclinical results of its BOXR T cell therapy platform and revealed it indicates a strong clinical path for its first transgene-expressing CAR-T cell as a potential treatment for solid tumors in adults with cancer. The results were presented at the Society for Immunotherapy of Cancer’s (SITC) 37th annual meeting taking place […]

November 10, 2022 - 4 minutesmins - By Liza Laws

News and Trends 10 Nov 2022

Parthenon and ImaginAb enter into license and supply agreement for anti-cancer therapies

Precision oncology company, Parthenon Therapeutics, and ImaginAb Inc., a global biotech have entered into a multi-year, non-exclusive license and supply agreement. Under the agreement terms, Parthenon will use ImaginAb’s CD8 ImmunoPET imaging technology in its phase 1 trial evaluating its lead compound, PRTH-101, which is expected to begin in 2023. ImaginAb is developing 89Zr crefmirlimab […]

November 10, 2022 - 4 minutesmins - By Liza Laws

More News! 10 Nov 2022

Eye disease therapies being developed after Breye Therapeutics’ €4M seed financing

Breye Therapeutics ApS a biopharmaceutical company developing therapies for retinal vascular diseases today (November 10) has closed a seed financing of €4 million led by Novo Holdings and Sound Bioventures. Diabetic retinopathy (DR) affects approximately 30% of all patients with diabetes and is the leading cause of blindness among working-age adults. Age-related macular degeneration (AMD) […]

November 10, 2022 - 4 minutesmins - By Liza Laws

News and Trends 10 Nov 2022

Avstera receives funding for cancer programs

Avstera Therapeutics Corp. has announced the completion of its seed round to advance its lead cancer programs geared toward targeting solid tumors. The company intends to use the $4.55 million proceeds to enable its lead highly specific HDAC6i for IND filing targeting locally advanced and metastatic solid tumors by the end of next year. “Tumor […]

November 10, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 10 Nov 2022

Minoryx and Neuraxpharm announce license agreement to further X-ALD treatment

Minoryx Therapeutics and Neuraxpharm Group have announced the completion of a strategic license agreement. Minoryx is a biotech company that focuses on the development of treatments for orphan central nervous system (CNS) disorders while the Neuraxpharm Group is a pharmaceutical company focused on CNS therapies. Under the agreement, Minoryx grants Neuraxpharm exclusive European rights to […]

November 10, 2022 - 3 minutesmins - By Liza Laws

More News! 9 Nov 2022

Sensorium closes $30M deal to advance drug discovery engine

Sensorium Therapeutics, announced the closing of a $30 million series a financing to advance its initial asset, SENS-01, and Biodynamic Discovery Platform (BDP). The platform is a drug discovery engine that rapidly identifies, synthesizes, and enhances targeted molecules as therapeutics. The round was led by Santé Ventures, a specialized healthcare and life sciences investment firm […]

November 9, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Nov 2022

GHO Capital and Vistria Group to acquire CDMO Alcami

Global Healthcare Opportunities, (GHO Capital Partners LLP), and The Vistria Group, have entered into a definitive agreement to acquire a controlling interest in Alcami Corporation, a pharmaceutical contract development and manufacturing organization (CDMO), from funds affiliated with Madison Dearborn Partners (MDP) and Ampersand Capital Partners. Headquartered in North Carolina, Alcami is involved in drug product […]

November 8, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

USA

Destiny Pharma’s XF-73 dermal infection project advances to safety study

Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy

New therapy transitions toxic immune cells from harmful to healing to fight effects of hyperinflammation in children

A biotech boom manifesting real results in rare pediatric diseases

Beyond Biotech podcast 22: PacBio, Sierra Space

SOTIO reveal potential treatment for adults with solid tumors at SITC meeting

Parthenon and ImaginAb enter into license and supply agreement for anti-cancer therapies

Eye disease therapies being developed after Breye Therapeutics’ €4M seed financing

Avstera receives funding for cancer programs

Minoryx and Neuraxpharm announce license agreement to further X-ALD treatment

Sensorium closes $30M deal to advance drug discovery engine

GHO Capital and Vistria Group to acquire CDMO Alcami

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!